(Q39430425)

English

WZ4002, a third-generation EGFR inhibitor, can overcome anoikis resistance in EGFR-mutant lung adenocarcinomas more efficiently than Src inhibitors

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

11 September 2017

WZ4002, a third-generation EGFR inhibitor, can overcome anoikis resistance in EGFR-mutant lung adenocarcinomas more efficiently than Src inhibitors (English)

1 reference

Europe PubMed Central

11 September 2017

1 reference

based on heuristic

inferred from title

author name string

Yuji Sakuma

1

1 reference

Europe PubMed Central

11 September 2017

Yukiko Yamazaki

2

1 reference

Europe PubMed Central

11 September 2017

Yoshiyasu Nakamura

3

1 reference

Europe PubMed Central

11 September 2017

Mitsuyo Yoshihara

4

1 reference

Europe PubMed Central

11 September 2017

Shoichi Matsukuma

5

1 reference

Europe PubMed Central

11 September 2017

Haruhiko Nakayama

6

1 reference

Europe PubMed Central

11 September 2017

Tomoyuki Yokose

7

1 reference

Europe PubMed Central

11 September 2017

Yoichi Kameda

8

1 reference

Europe PubMed Central

11 September 2017

Shiro Koizume

9

1 reference

Europe PubMed Central

11 September 2017

Yohei Miyagi

10

1 reference

Europe PubMed Central

11 September 2017

publication date

12 December 2011

1 reference

Europe PubMed Central

11 September 2017

Laboratory Investigation

1 reference

Europe PubMed Central

11 September 2017

92

1 reference

Europe PubMed Central

11 September 2017

371-383

1 reference

Europe PubMed Central

11 September 2017

3

1 reference

Europe PubMed Central

11 September 2017

https://scigraph.springernature.com/pub.10.1038/labinvest.2011.187

0 references

A logistic regression predictive model and the outcome of patients with resected lung adenocarcinoma of 2 cm or less in size.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2011.187

21 January 2018

Disruption of epithelial cell-matrix interactions induces apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2011.187

21 January 2018

Altered regulation of Src upon cell detachment protects human lung adenocarcinoma cells from anoikis

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2011.187

21 January 2018

CUB domain-containing protein 1 is a novel regulator of anoikis resistance in lung adenocarcinoma

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2011.187

21 January 2018

Lung adenocarcinoma cells floating in lymphatic vessels resist anoikis by expressing phosphorylated Src.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2011.187

21 January 2018

ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2011.187

21 January 2018

Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2011.187

21 January 2018

ABT-263, a Bcl-2 inhibitor, enhances the susceptibility of lung adenocarcinoma cells treated with Src inhibitors to anoikis

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2011.187

21 January 2018

Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2011.187

21 January 2018

Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2011.187

21 January 2018

Epidermal growth factor receptor mutations in lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2011.187

21 January 2018

Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2011.187

21 January 2018

Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2011.187

21 January 2018

Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2011.187

21 January 2018

SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2011.187

21 January 2018

The role of cooperativity with Src in oncogenic transformation mediated by non-small cell lung cancer-associated EGF receptor mutants

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2011.187

21 January 2018

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2011.187

21 January 2018

Poly(ADP-ribose) polymerase in DNA damage-response pathway: implications for radiation oncology

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2011.187

21 January 2018

Rapid and simple detection of hot spot point mutations of epidermal growth factor receptor, BRAF, and NRAS in cancers using the loop-hybrid mobility shift assay

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2011.187

21 January 2018

TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2011.187

21 January 2018

A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2011.187

21 January 2018

Src kinases as therapeutic targets for cancer

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2011.187

21 January 2018

Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2011.187

21 January 2018

EGFR mutants found in non-small cell lung cancer show different levels of sensitivity to suppression of Src: implications in targeting therapy.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2011.187

21 January 2018

Integrins in cancer: biological implications and therapeutic opportunities

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2011.187

21 January 2018

A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2011.187

21 January 2018

MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2011.187

21 January 2018

Asymmetric cancer cell division regulated by AKT

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2011.187

21 January 2018

Histone deacetylase inhibitors specifically kill nonproliferating tumour cells

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2011.187

21 January 2018

Malignant pleural effusion from lung adenocarcinoma treated by gefitinib

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2011.187

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2011.187

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/LABINVEST.2011.187

1 reference

Europe PubMed Central

11 September 2017

release_u3hwo4nw4vhttgblgjejdglp7y

1 reference

https://api.fatcat.wiki/v0/release/u3hwo4nw4vhttgblgjejdglp7y

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

11 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39430425&oldid=1842367706"